Details, Fiction and Z-LEHD-fmk
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To guage many intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Key demo goals have been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis people,